{"pmid":32124179,"title":"Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need.","text":["Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need.","Sci China Life Sci","Zhang, Tengyue","He, Yudi","Xu, Wenshuai","Ma, Aiping","Yang, Yanli","Xu, Kai-Feng","32124179"],"journal":"Sci China Life Sci","authors":["Zhang, Tengyue","He, Yudi","Xu, Wenshuai","Ma, Aiping","Yang, Yanli","Xu, Kai-Feng"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32124179","week":"202010|Mar 02 - Mar 08","doi":"10.1007/s11427-020-1660-2","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647633702912,"score":6.7365713,"similar":[{"pmid":32108352,"title":"Clinical trial analysis of 2019-nCoV therapy registered in China.","text":["Clinical trial analysis of 2019-nCoV therapy registered in China.","So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period.","J Med Virol","Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian","32108352"],"abstract":["So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period."],"journal":"J Med Virol","authors":["Zhang, Qi","Wang, Yakun","Qi, Changsong","Shen, Lin","Li, Jian"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32108352","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25733","keywords":["China","clinical trial","new coronavirus pneumonia","new drugs"],"source":"PubMed","locations":["Chinese","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["General Info","Treatment"],"weight":1,"_version_":1661359647493193728,"score":40.45571}]}